Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacey M Fernandes

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2012
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemiaJennifer R Brown, Megan Hanna, Bethany Tesar, et al.
Blood Advances|September 25, 2024
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemiaAbi Vijenthira, Virginia O Volpe, Aswin Sekar, et al.
Molecular Cancer|March 2, 2025
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemiaStephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, et al.
Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
Blood Cancer Discovery|April 17, 2023
METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLLYiming Wu, Meiling Jin, Mike Fernandez, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
American Journal of Hematology|December 29, 2020
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analysesJennifer R Brown, Sarah R Walker, Lisa N Heppler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2012
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemiaJennifer R Brown, Megan Hanna, Bethany Tesar, et al.
Blood Advances|September 25, 2024
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemiaAbi Vijenthira, Virginia O Volpe, Aswin Sekar, et al.
Molecular Cancer|March 2, 2025
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemiaStephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, et al.
Leukemia|November 7, 2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Alec Griffith, Svitlana Tyekucheva, et al.
Haematologica|May 7, 2013
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R Brown, Bradley Messmer, Lillian Werner, et al.
Blood Advances|April 11, 2019
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L Lampson, Haesook T Kim, Matthew S Davids, et al.
Blood Cancer Discovery|April 17, 2023
METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLLYiming Wu, Meiling Jin, Mike Fernandez, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
American Journal of Hematology|December 29, 2020
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analysesJennifer R Brown, Sarah R Walker, Lisa N Heppler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Pageof 6